Login / Signup

Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.

Wolfgang KruisBritta SiegmundKonrad LesniakowskiVladimir SimanenkovLudmila KhimionMarcin SobonGlebs DelmansSvetlana V MaksyashinaOleg A SablinJuris PokrotnieksYuriy MostovoyOlena DatsenkoSayar AbdulkhakovAndriy DorofeyevOlena LevchenkoOlga AlexeevaPavel AndreevIvan P KolesnikEmese MihalyOrest AbrahamovychMalgorzata BalutaNataliia KharchenkoNeshta ViacheslavYury UspenskiyMichael ViethRalf MohrbacherRalph MuellerRoland Greinwald
Published in: Journal of Crohn's & colitis (2022)
In patients with ulcerative proctitis, budesonide 4 mg suppository was non-inferior to budesonide 2 mg foam in efficacy, and both were safe and well tolerated.
Keyphrases
  • study protocol
  • clinical trial
  • ulcerative colitis
  • randomized controlled trial
  • rectal cancer
  • phase ii